文献速递淋巴瘤

间变性大细胞淋巴瘤与霍奇金淋巴瘤中EP300和CREBBP乙酰转移酶的分析及治疗靶向

Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
PubMed 文献 · Leukemia · 2022-12-01

研究探讨EP300和CREBBP乙酰转移酶在间变性大细胞淋巴瘤(ALCL)和霍奇金淋巴瘤(HL)中的生理作用,并评估靶向HAT或溴结构域的小分子抑制剂的治疗潜力。结果显示EP300而非CREBBP直接调控MYC/IRF4网络、CD30、IL10、LTA和PD-L1表达;抑制剂A-485和CPI-637在体外及异种移植小鼠模型中表现出强活性并抑制PD-L1介导的免疫逃逸。

要点

  • EP300而非CREBBP直接调控ALCL和HL的致癌MYC/IRF4网络及CD30、IL10、LTA、PD-L1表达。
  • EP300/CREBBP HAT抑制剂A-485和溴结构域抑制剂CPI-637在体外和异种移植模型中显示强抗肿瘤活性。
  • A-485和CPI-637可抑制PD-L1介导的肿瘤免疫逃逸。

核心结论

  • EP300和CREBBP在ALCL和HL中发挥不同作用,EP300直接调控致癌网络和免疫相关分子。
  • EP300/CREBBP HAT抑制剂A-485和溴结构域抑制剂CPI-637在体外和异种移植模型中具有强活性,并抑制PD-L1介导的免疫逃逸。

研究设计与样本

  • 研究探讨EP300和CREBBP在ALCL和HL中的生理作用,并利用靶向HAT或溴结构域活性的EP300/CREBBP小分子抑制剂评估治疗潜力。

主要发现

  • EP300而非CREBBP直接调控致癌MYC/IRF4网络、表面受体CD30、免疫调节细胞因子IL10和LTA以及免疫检查点蛋白PD-L1的表达。
  • EP300/CREBBP HAT抑制剂A-485和溴结构域抑制剂CPI-637在体外和异种移植小鼠模型中表现出强抗ALCL和HL活性。
  • A-485和CPI-637抑制PD-L1介导的肿瘤免疫逃逸。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (HL) share a similar cytological and high surface expression of CD30, and novel therapeutic strategies are needed. The EP300 and CREBBP acetyltransferases play essential roles in the pathogenesis of non-Hodgkin B cell lymphoma, but their functions in ALCL and HL are unknown. In the current study, we investigated the physiological roles of EP300 and CREBBP in both ALCL and HL, and exploited the therapeutic potential of EP300/CREBBP small molecule inhibitors that target either the HAT or bromodomain activities. Our studies demonstrated distinct roles for EP300 and CREBBP in supporting the viability of ALCL and HL, which was bolstered by the transcriptome analyses. Specifically, EP300 but not CREBBP directly modulated the expression of oncogenic MYC/IRF4 network, surface receptor CD30, immunoregulatory cytokines IL10 and LTA, and immune checkpoint protein PD-L1. Importantly, EP300/CREBBP HAT inhibitor A-485 and bromodomain inhibitor CPI-637 exhibited strong activities against ALCL and HL in vitro and in xenograft mouse models, and inhibited PD-L1 mediated tumor immune escape. Thus, our studies revealed critical insights into the physiological roles of EP300/CREBBP in these lymphomas, and provided opportunities for developing novel strategies for both targeted and immune therapies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wei W, Song Z, Chiba M, et al. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma. Leukemia. 2022. PMID: 36456744. doi:10.1038/s41375-022-01774-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。